Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News InflaRx NV IFRX

Healthcare Biotechnology
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously... see more

Recent & Breaking News (NDAQ:IFRX)

InflaRx to Present at Annual SVB Leerink Global Health Conference

GlobeNewswire February 8, 2022

InflaRx Announces New Pipeline Program - Oral C5aR Inhibitor

GlobeNewswire January 10, 2022

InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events

GlobeNewswire January 5, 2022

InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

GlobeNewswire January 5, 2022

InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)

GlobeNewswire November 15, 2021

InflaRx to Present at H.C. Wainwright 7th Annual Israel Conference

GlobeNewswire November 11, 2021

InflaRx Reports Third Quarter 2021 Financial & Operating Results

GlobeNewswire November 5, 2021

InflaRx to Present at the Credit Suisse 30th Annual Healthcare Conference

GlobeNewswire November 3, 2021

InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum

GlobeNewswire October 27, 2021

InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19

GlobeNewswire October 19, 2021

InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19

GlobeNewswire October 12, 2021

InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 9, 2021

InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

GlobeNewswire September 8, 2021

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

GlobeNewswire August 10, 2021

InflaRx to Present at the BTIG Virtual Biotechnology Conference

GlobeNewswire August 6, 2021

InflaRx Reports Second Quarter 2021 Financial & Operating Results

GlobeNewswire August 5, 2021

InflaRx to Present at the Raymond James Human Health Innovation Conference

GlobeNewswire June 17, 2021

InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

GlobeNewswire June 8, 2021

Tony Gibney Joins InflaRx Board of Directors

GlobeNewswire May 21, 2021

InflaRx Reports First Quarter 2021 Financial & Operating Results

GlobeNewswire May 12, 2021